National University Hospital, Singapore: Tuberculosis trials
The registry lists 13 Tuberculosis studies with National University Hospital, Singapore as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 7Phase 2 5Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Adjunctive Doxycycline for Central Nervous System TuberculosisRecruitingNCT06446245Phase 2
- Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary TuberculosisRecruitingNCT05473520Phase 3
- Rosuvastatin Evaluation as a Tuberculosis Treatment AdjunctStatus unknownNCT04504851Phase 2
- Evaluation of 11C-acetate PET Imaging as a Novel Approach to Detecting Pathology in Pulmonary TBStatus unknownNCT02972697Phase 1
- Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed ContactsStatus unknownNCT02967666Phase 1
- Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TBStatus unknownNCT02845570Phase 1
- Doxycycline in Human Pulmonary TuberculosisCompletedNCT02774993Phase 2
- Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy VolunteersCompletedNCT02700347Phase 1
- Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy VolunteersCompletedNCT02602509Phase 1
- Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy VolunteersCompletedNCT02393586Phase 1
- Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy VolunteersSuspendedNCT02387242Phase 1
- Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel BiomarkersCompletedNCT02381470Phase 2
- Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary TuberculosisStatus unknownNCT01638520Phase 2